For Investors
Our Motivation
Bringing a drug to market can cost up to $2B, yet clinical trials yield a 90% failure rate. Why? Current tools and assays can’t accurately predict how a drug will act once it enters a patient’s body. Even when drugs receive FDA approval, adverse drug reactions are the fourth leading cause of death in America. On top of that, up to 60% of prescribed medications are ineffective.
Syntensor helps investors and drug developers address both these challenges. They’re building models designed to better predict toxicity or lack of efficacy, the key causes of clinical trial failure, before the trials start. Improving the efficacy and safety of new medications could save companies billions of dollars in R&D costs. It could also save lives.
Our Business Model
Syntensor is developing models to predict drug efficacy and toxicity for clinical trials and individual patients, enabling informed decision-making for investors, drug developers, regulators and clinicians. Users can access Syntensor's models for predicting clinical trial outcomes via the Syntensor Terminal, a web app, enabling a SaaS-like business model.